US20230330158A1 - Intestinal microbiota bacteria and composition containing same for use in the prevention and/or treatment of diseases characterised by excess 2-hydroxyglutarate - Google Patents
Intestinal microbiota bacteria and composition containing same for use in the prevention and/or treatment of diseases characterised by excess 2-hydroxyglutarate Download PDFInfo
- Publication number
- US20230330158A1 US20230330158A1 US17/915,610 US202017915610A US2023330158A1 US 20230330158 A1 US20230330158 A1 US 20230330158A1 US 202017915610 A US202017915610 A US 202017915610A US 2023330158 A1 US2023330158 A1 US 2023330158A1
- Authority
- US
- United States
- Prior art keywords
- bacteria
- composition
- use according
- bacterium
- genus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 179
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 58
- 238000011282 treatment Methods 0.000 title claims abstract description 53
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 201000010099 disease Diseases 0.000 title claims abstract description 46
- 230000002265 prevention Effects 0.000 title claims abstract description 22
- 244000005709 gut microbiome Species 0.000 title claims abstract description 7
- 241001308569 Massiliomicrobiota Species 0.000 claims abstract description 41
- 241001465754 Metazoa Species 0.000 claims abstract description 37
- 241000148163 Negativibacillus Species 0.000 claims abstract description 29
- 241000755889 Christensenellaceae Species 0.000 claims abstract description 24
- 241000282412 Homo Species 0.000 claims abstract description 18
- 241000801624 Christensenella minuta Species 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 230000004770 neurodegeneration Effects 0.000 claims description 25
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 24
- 241000442146 Massiliomicrobiota timonensis Species 0.000 claims description 16
- 241000755920 Christensenella Species 0.000 claims description 14
- 241000056225 Negativibacillus massiliensis Species 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 12
- 241000914543 Christensenella massiliensis Species 0.000 claims description 11
- 241001254467 Christensenella timonensis Species 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 208000018360 neuromuscular disease Diseases 0.000 claims description 7
- 102000014461 Ataxins Human genes 0.000 claims description 6
- 108010078286 Ataxins Proteins 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000024777 Prion disease Diseases 0.000 claims description 6
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 6
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007897 gelcap Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 230000000529 probiotic effect Effects 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 33
- 239000002609 medium Substances 0.000 description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- 241001267951 Parasutterella Species 0.000 description 24
- 210000002569 neuron Anatomy 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000001963 growth medium Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 235000013372 meat Nutrition 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000003412 degenerative effect Effects 0.000 description 11
- 241000260425 Parasutterella excrementihominis Species 0.000 description 10
- 241000801561 Parasutterella secunda Species 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000000750 progressive effect Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 201000006762 D-2-hydroxyglutaric aciduria Diseases 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000007382 columbia agar Substances 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- -1 for example Substances 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 4
- 235000019175 phylloquinone Nutrition 0.000 description 4
- 239000011772 phylloquinone Substances 0.000 description 4
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 4
- 229960001898 phytomenadione Drugs 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 201000006753 2-hydroxyglutaric aciduria Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 201000006752 L-2-hydroxyglutaric aciduria Diseases 0.000 description 3
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
- 239000008246 gaseous mixture Substances 0.000 description 3
- 235000020993 ground meat Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 230000005748 tumor development Effects 0.000 description 3
- 235000012711 vitamin K3 Nutrition 0.000 description 3
- 239000011652 vitamin K3 Substances 0.000 description 3
- UZJBWEULCUZEGW-LAMMAJBHSA-N (3s,4s,5s)-2,2,3,4,5-pentahydroxyhexanedioic acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)C(O)(O)C(O)=O UZJBWEULCUZEGW-LAMMAJBHSA-N 0.000 description 2
- WWFDJIVIDXJAQR-FFWSQMGZSA-N 1-[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound COCCO[C@@H]1[C@H](O)[C@@H](COP(O)(=S)O[C@@H]2[C@@H](COP(S)(=O)O[C@@H]3[C@@H](COP(O)(=S)O[C@@H]4[C@@H](COP(O)(=S)O[C@@H]5[C@@H](COP(O)(=S)O[C@@H]6[C@@H](COP(O)(=S)O[C@@H]7[C@@H](COP(O)(=S)O[C@@H]8[C@@H](COP(O)(=S)O[C@@H]9[C@@H](COP(O)(=S)O[C@@H]%10[C@@H](COP(O)(=S)O[C@@H]%11[C@@H](COP(O)(=S)O[C@@H]%12[C@@H](COP(O)(=S)O[C@@H]%13[C@@H](COP(O)(=S)O[C@@H]%14[C@@H](COP(O)(=S)O[C@@H]%15[C@@H](COP(O)(=S)O[C@@H]%16[C@@H](COP(O)(=S)O[C@@H]%17[C@@H](COP(O)(=S)O[C@@H]%18[C@@H](CO)O[C@H]([C@@H]%18OCCOC)n%18cc(C)c(=O)[nH]c%18=O)O[C@H]([C@@H]%17OCCOC)n%17cc(C)c(N)nc%17=O)O[C@H]([C@@H]%16OCCOC)n%16cnc%17c(N)ncnc%16%17)O[C@H]([C@@H]%15OCCOC)n%15cc(C)c(N)nc%15=O)O[C@H]([C@@H]%14OCCOC)n%14cc(C)c(=O)[nH]c%14=O)O[C@H]([C@@H]%13OCCOC)n%13cc(C)c(=O)[nH]c%13=O)O[C@H]([C@@H]%12OCCOC)n%12cc(C)c(=O)[nH]c%12=O)O[C@H]([C@@H]%11OCCOC)n%11cc(C)c(N)nc%11=O)O[C@H]([C@@H]%10OCCOC)n%10cnc%11c(N)ncnc%10%11)O[C@H]([C@@H]9OCCOC)n9cc(C)c(=O)[nH]c9=O)O[C@H]([C@@H]8OCCOC)n8cnc9c(N)ncnc89)O[C@H]([C@@H]7OCCOC)n7cnc8c(N)ncnc78)O[C@H]([C@@H]6OCCOC)n6cc(C)c(=O)[nH]c6=O)O[C@H]([C@@H]5OCCOC)n5cnc6c5nc(N)[nH]c6=O)O[C@H]([C@@H]4OCCOC)n4cc(C)c(N)nc4=O)O[C@H]([C@@H]3OCCOC)n3cc(C)c(=O)[nH]c3=O)O[C@H]([C@@H]2OCCOC)n2cnc3c2nc(N)[nH]c3=O)O[C@H]1n1cnc2c1nc(N)[nH]c2=O WWFDJIVIDXJAQR-FFWSQMGZSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 241001110888 Advenella Species 0.000 description 2
- 229940126638 Akt inhibitor Drugs 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241001600148 Burkholderiales Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241001527061 Pelistega Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical group C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 108010079058 casein hydrolysate Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000006781 columbia blood agar Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 238000011201 multiple comparisons test Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000032147 negative regulation of DNA repair Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229950001015 nusinersen Drugs 0.000 description 2
- 229940000673 orphan drug Drugs 0.000 description 2
- 239000002859 orphan drug Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229960004181 riluzole Drugs 0.000 description 2
- 229960004136 rivastigmine Drugs 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000002630 speech therapy Methods 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- IOCJWNPYGRVHLN-MMALYQPHSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CSSC[C@H](N)C(O)=O IOCJWNPYGRVHLN-MMALYQPHSA-N 0.000 description 1
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- HWXBTNAVRSUOJR-VKHMYHEASA-N (S)-2-hydroxyglutaric acid Chemical class OC(=O)[C@@H](O)CCC(O)=O HWXBTNAVRSUOJR-VKHMYHEASA-N 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241001673062 Achromobacter xylosoxidans Species 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 241000108164 Advenella incenata Species 0.000 description 1
- 241001217929 Advenella kashmirensis Species 0.000 description 1
- 241000947856 Aeromonadales Species 0.000 description 1
- 241000702460 Akkermansia Species 0.000 description 1
- 241000702462 Akkermansia muciniphila Species 0.000 description 1
- 241000589013 Alcaligenaceae Species 0.000 description 1
- 241000588813 Alcaligenes faecalis Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000947840 Alteromonadales Species 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000606126 Bacteroidaceae Species 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241001135755 Betaproteobacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000560672 Brackiella Species 0.000 description 1
- 241000560678 Brackiella oedipodis Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 241001133594 Castellaniella Species 0.000 description 1
- 241001277508 Castellaniella defragrans Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 description 1
- 241001430149 Clostridiaceae Species 0.000 description 1
- 101710186775 D-2-hydroxyglutarate dehydrogenase Proteins 0.000 description 1
- 102100025481 D-2-hydroxyglutarate dehydrogenase, mitochondrial Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241001180360 Derxia Species 0.000 description 1
- 241001180351 Derxia gummosa Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241001609975 Enterococcaceae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000609971 Erysipelotrichaceae Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241001608234 Faecalibacterium Species 0.000 description 1
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000002375 Hand-Foot Syndrome Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 1
- 101001138081 Homo sapiens L-2-hydroxyglutarate dehydrogenase, mitochondrial Proteins 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- 241001404241 Kerstersia Species 0.000 description 1
- 241001212817 Kerstersia gyiorum Species 0.000 description 1
- 102100020920 L-2-hydroxyglutarate dehydrogenase, mitochondrial Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 241001112693 Lachnospiraceae Species 0.000 description 1
- 241001468155 Lactobacillaceae Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000203065 Methanobacteriaceae Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000007218 Mungan syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- RENSBUVSRYZDEF-UHFFFAOYSA-N OC(C(=O)O)CCC(=O)O.C(CCCC(=O)O)(=O)O Chemical compound OC(C(=O)O)CCC(=O)O.C(CCCC(=O)O)(=O)O RENSBUVSRYZDEF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000293010 Oligella Species 0.000 description 1
- 241000293016 Oligella urethralis Species 0.000 description 1
- 241000266824 Oscillospira Species 0.000 description 1
- 241000266823 Oscillospira guilliermondii Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241001643770 Pigmentiphaga Species 0.000 description 1
- 241001640450 Pigmentiphaga kullae Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 206010036802 Progressive external ophthalmoplegia Diseases 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- 241000939704 Pusillimonas Species 0.000 description 1
- 241000939703 Pusillimonas noertemannii Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000692845 Rikenellaceae Species 0.000 description 1
- 241000095588 Ruminococcaceae Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000123710 Sutterella Species 0.000 description 1
- 241000813827 Sutterellaceae Species 0.000 description 1
- 241001148476 Taylorella Species 0.000 description 1
- 241001148458 Taylorella equigenitalis Species 0.000 description 1
- 241000131694 Tenericutes Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241001425419 Turicibacter Species 0.000 description 1
- 241001678097 Turicibacter sanguinis Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241001430183 Veillonellaceae Species 0.000 description 1
- 241001261005 Verrucomicrobia Species 0.000 description 1
- 241000230320 Verrucomicrobiales Species 0.000 description 1
- 241001531197 [Eubacterium] hallii Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940005347 alcaligenes faecalis Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 150000004783 arabinoxylans Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000019960 autosomal dominant cerebellar ataxia type I Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000007431 btu medium Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 231100000584 environmental toxicity Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000009019 intestinal benign neoplasm Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 208000018356 neurometabolic disease Diseases 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Definitions
- the invention relates to the treatment of pathologies characterized by excess 2-hydroxyglutarate in humans or animals, in particular diseases having a degenerative effect on cells such as neurons, motor nerve cells, brain, colon, kidney, blood, skin, liver, lymph, prostate, thyroid, stomach, breast, pancreas, pituitary cancers, and 2-hydroxyglutaric aciduria.
- neurons are cells that do not divide and do not renew themselves. Thus, neuron damage or death leads to their permanent disappearance from the human or animal body.
- the progressive degeneration and death of nerve cells are at the origin of problems related to movement (called ataxia) or to mental functioning (called dementia), which are characteristics of neurodegenerative diseases.
- Alzheimer's disease dementia, Parkinson's disease and associated disorders
- prion diseases neuromuscular diseases
- Huntington's disease spinocerebellar ataxia
- progressive spinal muscular atrophy amyotrophic lateral sclerosis.
- Dementia is the most serious form of pathological brain aging. It causes an increasing impairment of memory and cognitive functions as well as behavioral disorders leading to a progressive loss of autonomy. It causes disabilities and dependency in the elderly.
- Alzheimer's disease corresponds to a decline in cognition and memory. Nerve cells are gradually being destroyed in regions of the brain related to memory and language. Over time, the affected person has more and more difficulty memorizing events, recognizing objects and faces, remembering the meaning of words and exercising judgment.
- the treatments offered consist in treating some of the patient's symptoms with drugs (Donepezil, Rivastigmine, Galantamine, Memantine) or in taking care of the patient in a non-pharmacological way (speech therapy, physiotherapy, osteopathy, psychology, occupational therapy, psychomotricity. These treatments are not satisfactory because they do not prevent the progression of the disease and treat certain disorders that are only intermittent.
- Parkinson's disease affects the central nervous system, responsible for progressive disorders such as slowed movements, tremors, rigidity and cognitive disorders. It is the second most common neurodegenerative disease, after Alzheimer's disease.
- Huntington's disease is a hereditary disease that is characterized by significant motor, cognitive and psychiatric disorders, and progresses until loss of autonomy and finally death. These symptoms can be classified into three major families.
- the treatments offered consist in treating the symptoms to relieve the patient and slow down his physical and psychological deterioration with psychotropic drugs, neuroleptic drugs and rehabilitation through physiotherapy and speech therapy. These treatments are not satisfactory because they do not treat the disease curatively.
- Prion diseases are diseases characterized in particular by a degeneration of the central nervous system. They are also called transmissible subacute spongiform encephalopathies (TSSEs). These diseases are caused by the accumulation in the brain of a normal, but malformed protein, the prion protein. These diseases are characterized by a rapid and fatal progression. The best known is Creutzfeldt-Jakob disease (CJD).
- CJD Creutzfeldt-Jakob disease
- Neuromuscular diseases are diseases that affect the motor nerve cells of the spinal cord or motor neurons (spinal muscular atrophy, amyotrophic lateral sclerosis), the roots and nerves of the limbs (peripheral neuropathies), the junction between the nerve and the muscle (myasthenia) and the muscle (myopathies). They can affect the motor skills of the legs or arms, but sometimes also other organs and functions that depend on the muscles (motor skills of the eyes, speech, swallowing, digestion, breathing, the heart). The cause can be genetic or due to a malfunction of the immune system (“autoimmune” disease) that will cause damage to the nerves (dysimmune neuropathies) or the neuromuscular junction (myasthenia) or inflammation of the muscles (myositis). There are other possible causes: drug or environmental toxicity, vitamin deficiency, endocrine or general diseases, infections.
- autoimmune immune system
- Spinocerebellar ataxia corresponds to an autosomal dominant cerebellar ataxia type 1. It is characterized by ataxia, progressive external ophthalmoplegia and other neurological manifestations.
- the treatments offered consist in directly treating the cause of the disease through surgery, blood-thinning drugs, antibiotics or steroids. Orphan drug treatments are also used. These treatments are not satisfactory because they are orphan drugs not developed for these indications, and the side effects can be varied: eosinophilia, leukopenia, thrombocytopenia, diarrhea, skin rash and increased liver enzymes.
- the other treatments can have the undesirable effect of bleeding, digestive disorders such as nausea, vomiting, diarrhea, allergies, photosensitization.
- Spinal muscular atrophies or anterior spinal muscular atrophies are a group of neuromuscular diseases characterized by progressive muscle weakness due to degeneration and loss of anterior motor neurons in the spinal cord and brainstem nuclei. These diseases are presented in four forms depending on the age of onset and the severity of the disease. Currently, the treatments offered consist of a drug treatment (Nusinersen, known as Spinraza®), which is not effective in all forms of these diseases and has adverse respiratory and infectious effects.
- Nusinersen known as Spinraza®
- Amyotrophic lateral sclerosis is a disease characterized by progressive degeneration of motor neurons in the cerebral cortex. It causes progressive paralysis of the entire skeletal musculature of the limbs, the torso and the cephalic end.
- the various brain cancers are also characterized by excess 2-hydroxyglutarate production in the sick person or animal.
- 2-hydroxyglutarate is known for its status as a marker for neurodegenerative diseases as well as its role as an oncometabolite in brain tumor development.
- 2-Hydroxyglutarate has a DNA repair inhibiting action. The production of high levels of 2-hydroxyglutarate results in the inhibition of DNA repair pathways in cancer cells, and therefore the accumulation of damaged DNA.
- 2-Hydroxyglutarate is also known for its role as a marker of renal cell carcinomas and in tissues under oxygen limitation or hypoxia conditions such as hepatocellular carcinomas or colon carcinomas; it thus has a role in kidney and colon cancers.
- 2-hydroxyglutarate Inhibition of DNA repair by 2-hydroxyglutarate has been reported in other types of cancer: blood, skin, liver, lymph, prostate, thyroid, stomach, breast, pancreas, pituitary (Ye, D., Guan, K.-L. & Xiong, Y. Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates. Trends in cancer 4, 151-165 (2018)).
- 2-Hydroxyglutaric aciduria is a group of neurometabolic diseases with a broad clinical spectrum ranging from severe neonatal manifestations to progressive forms, and asymptomatic cases, characterized biochemically by elevated levels of 2-hydroxyglutaric acid in plasma, cerebrospinal fluid and urine.
- L-2-hydroxyglutaric aciduria is characterized by psychomotor retardation, cerebellar ataxia and epilepsy, and D-2-hydroxyglutaric aciduria (see this term) by variable metabolic, neurological and dysmorphic manifestations.
- the main cancer treatments are chemotherapy and radiotherapy, which have limited effectiveness allowing a low survival rate and very heavy side effects such as hair loss, nausea and vomiting, diarrhea, decrease in white blood cells, red blood cells and platelets, lesions in the mouth, numbness or tingling sensations in the hands or feet, skin disorders and hand-foot syndrome, changes in the color and weakening of the nails, muscle and joint pain, menstrual cycle disorders, fatigue disorders, allergic reactions, damage to healthy cells by irradiation of healthy tissue next to the tumor, sexual disorders, fertility problems, inflammatory reaction, effects on blood cells.
- the invention targets the use of specific bacteria of the human intestinal microbiota, in particular bacteria of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus.
- Christensenellaceae Bacteria of the family Christensenellaceae, including the genus Christensenella , have already been studied and described. This is the case in particular for Christensenella minuta, Christensenella massiliensis and Christensenella timonensis. Christensenella minuta in particular was described for the first time in 2012. In 2014, a study showed that it was the most heritable taxon in a cohort of British twins and that its presence is associated with a low body mass index. This correlation between Christensenella minuta and low body mass index was then observed in a dozen studies published since 2014 in geographically diverse populations. Finally, patent application US 2018/255819 describes the use of bacteria from the Christensenellaceae family in the treatment of obesity.
- Parasutterella genus Bacteria of the Parasutterella genus have already been studied and described. This is particularly the case for Parasutterella excrementihominis and Parasutterella secunda , which have been observed in several studies, without causal explanation. Parasutterella excrementihominis was first described in 2009 and Parasutterella secunda was first described in 2011. Other species have also been studied. This is the case for Parasutterella mc1, which has been associated with the abundance of certain metabolites in healthy mice.
- Negativibacillus genus Bacteria of the Negativibacillus genus have been described. This is the case for Negativibacillus massiliensis , which was described in 2016. Bacteria of the Negativibacillus genus were characterized according to the description presented in “ Negativibacillus massiliensis ” gen. Nov., sp. Nov., isolated from human left colon, D. Spainboni, M. Mailhe, V. Vitton, C. Andrieu, P.-E. Fournier, D. Raoult, New Microbe and New Infect 2017; 17: 36-38. No therapeutic use of bacteria of the Negativibacillus genus has ever been described or envisaged.
- Massiliomicrobiota timonensis and Massiliomicrobiota escudieri are known in particular.
- Massiliomicrobiota timonensis was described for the first time in 2016.
- Massiliomicrobiota escudieri was described for the first time in 2018.
- Bacteria of the Massiliomicrobiota genus have been characterized according to the description presented in “ Massiliomicrobiota timonensis ,” a new bacterial species isolated from the human gut, S. Ndongo, S. Khelaifia, P.-E. Fournier, D. Raoult, New Microbe and New Infect 2016; 13: 25-26 and in “ Massiliomicrobiota escudieri sp. nov.
- the subject of the invention is a bacterium of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one disease characterized by excess 2-hydroxyglutarate in humans or animals, in particular neurodegenerative diseases and cancers.
- such bacteria when they are administered to a human or an animal exhibiting a neurodegenerative disease or cancer, are capable of acting on the excess 2-hydroxyglutarate produced in these diseases.
- the bacteria of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus are preferably used in compositions.
- the invention therefore also relates to compositions comprising at least one bacterium of the Christensenellaceae family, preferably of the Christensenella genus, and/or a bacterium of the Parasutterella genus and/or a bacterium of the Negativibacillus genus and/or a bacterium of the Massiliomicrobiota genus, for its use in the prevention or treatment of diseases characterized by excess 2-hydroxyglutarate in humans or animals, in particular in the prevention or treatment of neurodegenerative diseases and/or cancers.
- FIG. 1 demonstrates the antiproliferative effect of the supernatants of bacteria according to the invention, in particular 3 strains of C. minuta on a human colon adenocarcinoma cell line, the HTC-116 line, after 24 and 48 hours of treatment.
- FIG. 2 demonstrates the antiproliferative effect of the supernatants of bacteria according to the invention, in particular 3 strains of C. minuta on a human hepatocarcinoma cell line, the HepG2 line, after 24 and 48 hours of treatment.
- excess or “hyperproduction” of 2-hydroxyglutarate means an excessive production of 2-hydroxyglutarate relative to the production in a healthy person or animal without pathology.
- disease characterized by excess 2-hydroxyglutarate or “disease characterized by hyperproduction of 2-hydroxyglutarate” means a disease whereof at least one cause is the excess or hyperproduction of 2-hydroxyglutarate in the body of the sick person or animal. This may in particular include a neurodegenerative disease or cancer.
- marker of a disease means a molecule or a substance whose assay makes it possible to follow the evolution of said disease.
- the invention therefore relates to a bacterium of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one disease characterized by excess 2-hydroxyglutarate in humans or animals.
- Negativibacillus massiliensis Bacteria of the Negativibacillus genus have been characterized according to the description presented in “ Negativibacillus massiliensis ” gen. Nov., sp. Nov., isolated from human left colon, D. Jamaicaboni, M. Mailhe, V. Vitton, C. Andrieu, P.-E. Fournier, D. Raoult, New Microbe and New Infect 2017; 17: 36-38 and in “ Massiliomicrobiota escudieri sp. nov. isolated as part of a culturomics exploration of the gut microbiota of renal cancer patients,” unpublished, Tidjani Alou, M., Derosa, L. and Zitvogel, L., submitted (11 Jun. 2018) U1015, Institut Gustave Roussy, 114 rue Edouard Vaillant, Villejuif 94800, France, Metropolitan.
- Massiliomicrobiota timonensis Bacteria of the Massiliomicrobiota timonensis ,” a new bacterial species isolated from the human gut, S. Ndongo, S. Khelaifia, P.-E. Fournier, D. Raoult, New Microbe and New Infect 2016; 13: 25-26.
- the invention relates to a bacterium of the Christensenellaceae family, in particular of the Christensenella genus, and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one neurodegenerative disease and/or of at least one cancer in humans or animals.
- the invention relates to a bacterium of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one neurodegenerative disease chosen from Alzheimer's disease, dementia, Parkinson's disease and associated disorders, prion diseases, neuromuscular diseases, Huntington's disease, spinocerebellar ataxia, progressive spinal muscular atrophy and amyotrophic lateral sclerosis.
- a neurodegenerative disease chosen from Alzheimer's disease, dementia, Parkinson's disease and associated disorders, prion diseases, neuromuscular diseases, Huntington's disease, spinocerebellar ataxia, progressive spinal muscular atrophy and amyotrophic lateral sclerosis.
- the invention relates to a bacterium of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one brain and/or kidney and/or liver and/or colon cancer, in humans or animals.
- the invention relates to a bacterium of the Christensenellaceae family and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one brain and/or kidney and/or liver and/or colon cancer, in humans or animals.
- the invention relates to a bacterium of the Parasutterella genus, for its use in the prevention and/or treatment of at least one neurodegenerative disease, preferably chosen from Alzheimer's disease, dementia, Parkinson's disease and related disorders, prion diseases, neuromuscular diseases, Huntington's disease, spinocerebellar ataxia, progressive spinal muscular atrophy and amyotrophic lateral sclerosis.
- a neurodegenerative disease preferably chosen from Alzheimer's disease, dementia, Parkinson's disease and related disorders, prion diseases, neuromuscular diseases, Huntington's disease, spinocerebellar ataxia, progressive spinal muscular atrophy and amyotrophic lateral sclerosis.
- the bacteria of the Christensenellaceae family and/or the bacteria of the Parasutterella genus and/or the bacteria of the Negativibacillus genus and/or the bacteria of the Massiliomicrobiota genus when they are administered to a human or an animal presenting a neurodegenerative disease, are capable of acting on the excess molecules produced in a neurodegenerative disease or cancer, in particular on 2-hydroxyglutarate.
- the decrease in the amount of 2-hydroxyglutarate is a sign of the reduction in these diseases with a degenerative effect on neurons, that is to say, the bacteria at the origin of this production are less stimulated. From then on, the excessive production responsible for the disease having a degenerative effect is slowed down and the system gradually returns to normal.
- a substrate of 2-hydroxyglutarate, glutarate decreases when 2-hydroxyglutarate increases.
- a return to normal through a decrease in 2-hydroxyglutarate is accompanied by an increase in glutarate.
- the decrease in the synthesis of 2-hydroxyglutarate is the sign of reduced inhibition of the DNA repair pathways, that is to say, the bacteria at the origin of this production are less stimulated. From then on, the excessive production responsible for DNA repair inhibition is slowed down and the system gradually returns to normal.
- a substrate of 2-hydroxyglutarate, glutarate decreases when 2-hydroxyglutarate increases.
- a return to normal through a decrease in 2-hydroxyglutarate is accompanied by an increase in glutarate.
- 2-hydroxyglutaric aciduria the reduction in 2-hydroxyglutarate synthesis is the sign of the reduction in the clinical symptoms associated with this disease.
- a substrate of 2-hydroxyglutarate, glutarate decreases when 2-hydroxyglutarate increases.
- a decrease in 2-hydroxyglutarate is accompanied by an increase in glutarate.
- the useful bacteria according to the invention are administered to humans or animals in an effective quantity for an action on 2-hydroxyglutarate, that is to say, to reduce its production in the body.
- the bacterium or bacteria can be administered at a dose of 10 9 to 10 12 colony-forming units (CFU) per day, regardless of the weight of the person or animal. It is preferably a single dose, i.e., administered once daily, or a dose before each meal (three times a day).
- the useful bacterium or bacteria according to the invention are:
- the useful bacterium or bacteria according to the invention are preferably administered in a composition.
- composition Comprising Bacteria According to the Invention
- the invention therefore also relates to a composition
- a composition comprising at least one bacterium of the Christensenellaceae family and/or a bacterium of the Parasutterella genus and/or a bacterium of the Negativibacillus genus and/or a bacterium of the Massiliomicrobiota genus, in the prevention and/or treatment of diseases characterized by excess 2-hydroxyglutarate, in particular neurodegenerative diseases and/or cancers, in humans or animals.
- the bacterium or bacteria are present in an effective amount in the composition, allowing an effect on the 2-hydroxyglutarate and on the disease(s) to be treated, in particular the neurogenerative diseases and/or cancers, of the treated persons or animals.
- the useful composition according to the invention comprises 10 6 to 10 12 colony-forming units (CFU) of bacteria of the Christensenellaceae family and/or of bacteria of the Parasutterella genus and/or of bacteria of the Negativibacillus genus and/or of bacteria of the Massiliomicrobiota genus per daily dose of composition to be administered.
- CFU colony-forming units
- this corresponds to a daily dose of bacteria to be administered, regardless of the weight of the person or the animal.
- this dose is administered once per day.
- the useful composition according to the invention may be in liquid form. It may in particular comprise bacteria of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus and a culture medium for said bacteria that makes it possible to preserve them.
- This medium may be, for example, Columbia agar medium for bacteria of the Christensenellaceae family, bacteria of the Negativibacillus genus, bacteria of the Massiliomicrobiota genus, or BTU medium for bacteria of the Parasutterella genus, anaerobic enriched with sheep blood, or an equivalent medium containing no animal byproduct.
- the useful composition according to the invention may be in solid form.
- the bacteria may be present in freeze-dried form, and may also comprise excipients such as, for example, microcrystalline cellulose, lactose, sucrose, fructose, levulose, starches, stachyose, raffinose, amylum, calcium lactate, magnesium sulphate, sodium citrate, calcium stearate, polyvinylpyrrolidone, maltodextrin, galactooligosaccharides, fructooligosaccharides, pectins, beta-glucans, lactoglobulins, isomaltooligosaccharides, polydextroses, sorbitol and/or glycerol.
- excipients such as, for example, microcrystalline cellulose, lactose, sucrose, fructose, levulose, starches, stachyose, raffinose, amylum, calcium lactate, magnesium sulphate
- compositions according to the invention may in particular be in the form of powder, microencapsulated powder, gelcap, capsule, tablet, lozenge, granules, emulsion, suspension or suppository. According to a particularly suitable embodiment, they may be in a gastro-resistant form, such as a coated tablet containing microencapsulated bacteria.
- compositions When the compositions are in solid form, they are preferably packaged in capsules or in a coating hermetically sealed against light and oxygen, maintained at an ambient temperature of between 15° C. and 40° C. and a humidity level between 3% and 70%.
- the bacteria can be used alive, or inactivated, for example by heat, exposure to an appropriate pH, gamma radiation or high pressure.
- At least part of the bacteria is made up of live bacteria, in particular at least 50% (by number), even more preferably at least 90% (by number).
- the bacteria present in the useful composition according to the invention are at least 50% living bacteria (by number), preferably at least 90% living bacteria (by number), and even more preferentially all living.
- the useful bacteria according to the invention can be administered orally, topically, through the lungs (inhalation) or rectally.
- compositions according to the invention in addition to the useful bacteria according to the invention, can comprise other compounds, such as:
- Chemotherapy drugs including targeted therapies or biotherapies, hormone therapy or immunotherapy
- the invention is now illustrated by examples of useful bacteria according to the invention, methods for culturing these bacteria, examples of compositions containing them and test results demonstrating the effectiveness of bacteria of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus on 2-hydroxyglucarate and consequently on the diseases induced by an excess of this molecule.
- the Christensenella minuta bacteria can be cultured according to the operating protocol described below.
- the Christensenella massiliensis bacteria can be cultured according to the operating protocol described below.
- the composition of the meat filtrate is shown in Table 2.
- the meat filtrate is prepared as follows.
- the bacteria must be grown under anaerobic conditions at 37° C.
- the Christensenella timonensis bacteria can be cultivated according to the same procedure as that described in Example 2 for Christensenella massiliensis.
- the Parasutterella excrementihominis bacteria can be cultured according to the operating protocol described below.
- BTU (ground meat medium+Formate/fumarate)+5% bovine serum
- Boil under a Nitrogen atmosphere add 0.5 g/l of cystine and adjust the pH to 7.0.
- Haemin solution dissolve 50 mg of Haemin in 1 mL of 1 N NaOH, add 100 mL of distilled water and sterilize by filtration, store refrigerated.
- Vitamin K1 solution dissolve 0.1 mL of vitamin K1 in 20 mL of 95% ethanol and sterilize by filtration. Store refrigerated in an amber bottle.
- Vitamin K3 solution
- the Parasutterella secunda bacteria can be cultured according to the operating protocol described below.
- the Negativibacillus massiliensis bacteria can be cultured according to the operating protocol described below.
- Example 7 Massiliomicrobiota timonensis
- Massiliomicrobiota timonensis can be cultivated according to the operating protocol described as follows:
- Example 8 Massiliomicrobiota escudieri
- the Massiliomicrobiota escudieri bacteria can be cultivated according to the same procedure as that described in Example 7 for Massiliomicrobiota timonensis.
- Example 9 Useful Composition of Christensenella minuta According to the Invention in Liquid Form
- compositions according to the invention in liquid form are a composition comprising Christensenella minuta 10 9 CFU/mL in the RCM anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- Example 9 The composition of Example 9 was obtained from an RCB (“research cell bank”) prepared with Christensenella minuta 10 10 CFU/mL and stored frozen at ⁇ 20° C. in a bag hermetically sealed to oxygen.
- RCB search cell bank
- the frozen composition must be warmed to room temperature until a liquid form is found before use.
- Example 10 Useful Composition of Christensenella massiliensis According to the Invention in Liquid Form
- compositions according to the invention in liquid form are a composition comprising Christensenella massiliensis 10 9 CFU/mL in the carboxymethylcellulose anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- Example 10 The composition of Example 10 was obtained from an RCB (“research cell bank”) prepared with Christensenella massiliensis 10 10 CFU/mL and stored frozen at ⁇ 20° C. in a bag hermetically sealed to oxygen.
- RCB search cell bank
- the frozen composition must be warmed to room temperature until a liquid form is found before use.
- Example 11 Useful Composition of Christensenella timonensis According to the Invention in Liquid Form
- compositions according to the invention in liquid form are a composition comprising Christensenella timonensis 10 9 CFU/mL in the carboxymethylcellulose anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- Example 11 The composition of Example 11 was obtained from an RCB (“research cell bank”) prepared with Christensenella timonensis 10 10 CFU/mL and stored frozen at ⁇ 20° C. in a bag hermetically sealed to oxygen.
- RCB search cell bank
- the frozen composition must be warmed to room temperature until a liquid form is found before use.
- Example 12 Useful Composition of Parasutterella excrementihominis According to the Invention in Liquid Form
- compositions according to the invention in liquid form are a composition comprising Parasutterella excrementihominis 10 9 CFU/mL in the BTU anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- Example 12 The composition of Example 12 was obtained from an RCB (“research cell bank”) prepared with Parasutterella excrementihominis 10 10 CFU/mL and stored frozen at ⁇ 20° C. in a bag hermetically sealed to oxygen.
- RCB search cell bank
- the frozen composition must be warmed to room temperature until a liquid form is found before use.
- Example 13 Useful Composition of Parasutterella secunda According to the Invention in Liquid Form
- compositions according to the invention in liquid form are a composition comprising Parasutterella secunda 10 9 CFU/mL in the EG culture medium or the Columbia anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- Example 13 The composition of Example 13 was obtained from an RCB (“research cell bank”) prepared with Parasutterella secunda 10 10 CFU/mL and stored frozen at ⁇ 20° C. in a bag hermetically sealed to oxygen.
- RCB search cell bank
- the frozen composition must be warmed to room temperature until a liquid form is found before use.
- Example 14 Useful Composition of Negativibacillus massiliensis According to the Invention in Liquid Form
- compositions according to the invention in liquid form are a composition comprising Negativibacillus massiliensis 10 9 CFU/mL in the EG culture medium or the Columbia anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- Example 14 The composition of Example 14 was obtained from an RCB (“research cell bank”) prepared with Negativibacillus massiliensis 10 10 CFU/mL and stored frozen at ⁇ 20° C. in a bag hermetically sealed to oxygen.
- RCB search cell bank
- the frozen composition must be warmed to room temperature until a liquid form is found before use.
- Example 15 Useful Composition of Massiliomicrobiota timonensis According to the Invention in Liquid Form
- compositions according to the invention in liquid form are a composition comprising Massiliomicrobiota timonensis 10 9 CFU/mL in the EG culture medium or the Columbia anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- Example 15 was obtained from an RCB (“research cell bank”) prepared with Massiliomicrobiota timonensis 10 10 CFU/mL and stored frozen at ⁇ 20° C. in a bag hermetically sealed to oxygen.
- RCB search cell bank
- the frozen composition must be warmed to room temperature until a liquid form is found before use.
- Example 16 Useful Composition of Massiliomicrobiota Escudieri According to the Invention in Liquid Form
- compositions according to the invention in liquid form are a composition comprising Massiliomicrobiota escudieri 10 9 CFU/mL in the EG culture medium or the Columbia anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- Example 16 The composition of Example 16 was obtained from an RCB (“research cell bank”) prepared with Massiliomicrobiota escudieri 10 10 CFU/mL and stored frozen at ⁇ 20° C. in a bag hermetically sealed to oxygen.
- RCB search cell bank
- the frozen composition must be warmed to room temperature until a liquid form is found before use.
- Example 17 Composition of at Least One Useful Bacterium According to the Invention in Liquid Form Mixed with at Least One Other Distinct Useful Bacterium According to the Invention in Liquid Form
- An example of a useful composition according to the invention in liquid form can be obtained by mixing at least one composition of Examples 9 to 16 with at least one distinct composition from Examples 9 to 16.
- Example 18 Useful Composition According to the Invention in Solid Form
- An example of a useful composition according to the invention in freeze-dried form can be obtained by freeze-drying one of the compositions of Examples 9 to 17 in the frozen state.
- the objective of this study is to demonstrate in vitro the treatment effect of bacteria according to the invention on neurodegenerative diseases and cancers.
- the demonstration was carried out on 2-hydroxyglutarate and its precursor, glutarate.
- Relative peak area (metabolite peak area)/(internal standard peak area ⁇ amount of sample).
- a negative correlation is observed between the bacteria according to the invention and 2-hydroxyglutarate as well as a positive correlation between the bacteria according to the invention and glutarate, which demonstrates a protective effect of bacteria of the Massiliomicrobiota genus against neurodegenerative diseases and cancers.
- the bacteria according to the invention are able to act by decreasing the production of 2-hydroxyglutarate. They can therefore be used to prevent and/or treat neurodegenerative diseases and cancers.
- the objective of this study is to demonstrate in vitro the effect of bacteria according to the invention, in particular of C. minuta on the proliferation of tumor cells.
- the effect of the supernatants was evaluated after 24 h and 48 h of treatment of a human colon adenocarcinoma cell line, the HCT-116 line. The procedure is described below.
- the HCT-116 cell line was maintained in culture in McCoy's 5 A medium supplemented with 10% fetal calf serum (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich) in a humid incubator at 37° C. and 5% CO2.
- the HCT-116 cells were seeded at a density of 10,000 cells/well in a total volume of 100 ⁇ l in a 96-well plate. After 24 h of incubation, the culture medium was removed from the adherent cells and new medium supplemented with 10% stationary phase supernatant of C. minuta was added (DSMZ: DSM22607, C. minuta 1, C. minuta 2 or C. minuta 3 and in GAM control (bacterial culture medium)). Each condition was done in 4 replicates. The cells were incubated for an additional 24 or 48 hours.
- Cell proliferation was determined using the CellTiter-Glo 2.0 assay kit (Promega). The measurements were carried out according to the manufacturer's instructions. Briefly, the plates were removed from the incubator and allowed to equilibrate at room temperature for 30 min, and an equal volume of CellTiter-Glo 2.0 reagent was added directly to the wells (100 ⁇ l). The plates were stirred at 300 rpm for 2 min using a rotary stirrer, then incubated at room temperature for 10 min. The reaction mixture was then transferred to a white-walled 96-well plate and the luminescent signal was measured using a microplate reader (FLUOstar Omega, BMG Labtech).
- a microplate reader FLUOstar Omega, BMG Labtech
- Akt Inhibitor VIII is used as a positive control for blocking cell proliferation.
- the supernatants of the various tested bacteria according to the invention induce a reduction in the proliferation of tumor line HCT-116, making it possible to indicate a beneficial effect of the bacteria according to the invention in the inhibition of tumor development.
- the objective of this study is to demonstrate in vitro the effect of bacteria according to the invention, in particular of C. minuta on the proliferation of tumor cells.
- the effect of the supernatants was evaluated after 24 h and 48 h of treatment of a human adenocarcinoma cell line, the HepG2 line. The procedure is described below.
- the HepG2 cell line was maintained in culture in DMEM medium supplemented with 10% fetal calf serum (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich) in a humid incubator at 37° C. and 5% CO2.
- the cell treatment and the proliferation test are identical to the test previously described on the HCT-116 line.
- Akt Inhibitor VIII is used as a control for blocking cell proliferation.
- the supernatants of the tested bacteria according to the invention induce a reduction in the proliferation of tumor line HepG2, making it possible to indicate a beneficial effect of the bacteria according to the invention in the inhibition of tumor development.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The subject matter of the invention is a human intestinal microbiota bacterium selected from bacteria in the Christensenellaceae family, bacteria of the genus Negativibacillus and bacteria of the genus Massiliomicrobiota, or a composition containing same, for use in the prevention and/or treatment of diseases characterized by excess 2-hydroxyglutarate in humans or animals.
Description
- The invention relates to the treatment of pathologies characterized by excess 2-hydroxyglutarate in humans or animals, in particular diseases having a degenerative effect on cells such as neurons, motor nerve cells, brain, colon, kidney, blood, skin, liver, lymph, prostate, thyroid, stomach, breast, pancreas, pituitary cancers, and 2-hydroxyglutaric aciduria.
- Diseases having a degenerative effect on neurons are disabling chronic diseases with a slow and discreet evolution that are characterized by the progressive loss of neurons in more or less localized regions of the nervous system, leading to cognitive, motor or perceptual complications. Ultimately, they can lead to death.
- Indeed, neurons are cells that do not divide and do not renew themselves. Thus, neuron damage or death leads to their permanent disappearance from the human or animal body. However, the progressive degeneration and death of nerve cells are at the origin of problems related to movement (called ataxia) or to mental functioning (called dementia), which are characteristics of neurodegenerative diseases.
- Diseases with a degenerative effect on neurons are generally related to aging and often affect people over 65 years of age. Known in particular are Alzheimer's disease, dementia, Parkinson's disease and associated disorders, prion diseases, neuromuscular diseases, Huntington's disease, spinocerebellar ataxia, progressive spinal muscular atrophy and amyotrophic lateral sclerosis.
- Dementia is the most serious form of pathological brain aging. It causes an increasing impairment of memory and cognitive functions as well as behavioral disorders leading to a progressive loss of autonomy. It causes disabilities and dependency in the elderly.
- Alzheimer's disease corresponds to a decline in cognition and memory. Nerve cells are gradually being destroyed in regions of the brain related to memory and language. Over time, the affected person has more and more difficulty memorizing events, recognizing objects and faces, remembering the meaning of words and exercising judgment.
- Currently, the treatments offered consist in treating some of the patient's symptoms with drugs (Donepezil, Rivastigmine, Galantamine, Memantine) or in taking care of the patient in a non-pharmacological way (speech therapy, physiotherapy, osteopathy, psychology, occupational therapy, psychomotricity. These treatments are not satisfactory because they do not prevent the progression of the disease and treat certain disorders that are only intermittent.
- Parkinson's disease affects the central nervous system, responsible for progressive disorders such as slowed movements, tremors, rigidity and cognitive disorders. It is the second most common neurodegenerative disease, after Alzheimer's disease.
- Currently, the treatments offered consist of:
-
- drug treatments to compensate for the lack of dopamine by mimicking the action of dopamine, by administering a substance that will be transformed into dopamine, by giving a substance that blocks the breakdown of dopamine,
- surgical treatments consisting in stimulating deep brain function (implantation of electrodes in the brain). These treatments are not satisfactory because they have many side effects (nausea, vomiting, dyskinesia, behavioral disorders such as new addictions) and they improve the patient's quality of life but do not stop the progression of the disease.
- Huntington's disease is a hereditary disease that is characterized by significant motor, cognitive and psychiatric disorders, and progresses until loss of autonomy and finally death. These symptoms can be classified into three major families.
- Currently, the treatments offered consist in treating the symptoms to relieve the patient and slow down his physical and psychological deterioration with psychotropic drugs, neuroleptic drugs and rehabilitation through physiotherapy and speech therapy. These treatments are not satisfactory because they do not treat the disease curatively.
- Prion diseases are diseases characterized in particular by a degeneration of the central nervous system. They are also called transmissible subacute spongiform encephalopathies (TSSEs). These diseases are caused by the accumulation in the brain of a normal, but malformed protein, the prion protein. These diseases are characterized by a rapid and fatal progression. The best known is Creutzfeldt-Jakob disease (CJD).
- There is currently no treatment.
- Neuromuscular diseases are diseases that affect the motor nerve cells of the spinal cord or motor neurons (spinal muscular atrophy, amyotrophic lateral sclerosis), the roots and nerves of the limbs (peripheral neuropathies), the junction between the nerve and the muscle (myasthenia) and the muscle (myopathies). They can affect the motor skills of the legs or arms, but sometimes also other organs and functions that depend on the muscles (motor skills of the eyes, speech, swallowing, digestion, breathing, the heart). The cause can be genetic or due to a malfunction of the immune system (“autoimmune” disease) that will cause damage to the nerves (dysimmune neuropathies) or the neuromuscular junction (myasthenia) or inflammation of the muscles (myositis). There are other possible causes: drug or environmental toxicity, vitamin deficiency, endocrine or general diseases, infections.
- The treatments are different depending on the cause of the disease. In genetic diseases, therapeutic trials are in their early stages, and no routine treatment exists. When there is an anomaly in the cell metabolism, there are often drugs that aim to alleviate the consequences of this deficiency. In dysimmune diseases, there are many treatments that may be effective. However, undesirable side effects are known, such as hematologic effects.
- Spinocerebellar ataxia corresponds to an autosomal dominant cerebellar ataxia type 1. It is characterized by ataxia, progressive external ophthalmoplegia and other neurological manifestations.
- Currently, the treatments offered consist in directly treating the cause of the disease through surgery, blood-thinning drugs, antibiotics or steroids. Orphan drug treatments are also used. These treatments are not satisfactory because they are orphan drugs not developed for these indications, and the side effects can be varied: eosinophilia, leukopenia, thrombocytopenia, diarrhea, skin rash and increased liver enzymes. The other treatments can have the undesirable effect of bleeding, digestive disorders such as nausea, vomiting, diarrhea, allergies, photosensitization.
- Spinal muscular atrophies or anterior spinal muscular atrophies are a group of neuromuscular diseases characterized by progressive muscle weakness due to degeneration and loss of anterior motor neurons in the spinal cord and brainstem nuclei. These diseases are presented in four forms depending on the age of onset and the severity of the disease. Currently, the treatments offered consist of a drug treatment (Nusinersen, known as Spinraza®), which is not effective in all forms of these diseases and has adverse respiratory and infectious effects.
- Amyotrophic lateral sclerosis, or Charcot, is a disease characterized by progressive degeneration of motor neurons in the cerebral cortex. It causes progressive paralysis of the entire skeletal musculature of the limbs, the torso and the cephalic end.
- Only one drug is currently offered to treat amyotrophic lateral sclerosis. It is Riluzole®, but this drug is not effective, does not improve the quality of life and prolongs survival by only a few months.
- All diseases with a degenerative effect on neurons are characterized by excess production of 2-hydroxyglutarate by the sick person or animal (Gibson, K2. M., Craigen, W., Herman, G. E. & Jakobs, C. D-2-Hydroxyglutaric Aciduria in a Newborn with Neurological Abnormalities: A New Neurometabolic Disorder? J. Inher. Metab. Dis 16, (1993); Ma, S. et al. L2hgdh Deficiency Accumulates I-2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration. Mol. Cell. Biol. (2017). doi:10.1128/MCB.00492-16).
- Accumulation of 2-hydroxyglutarate causes abnormal myelination, disrupts neuronal stem cell homeostasis and increases central nervous system cell mortality.
- The various brain cancers are also characterized by excess 2-hydroxyglutarate production in the sick person or animal. Indeed, 2-hydroxyglutarate is known for its status as a marker for neurodegenerative diseases as well as its role as an oncometabolite in brain tumor development. 2-Hydroxyglutarate has a DNA repair inhibiting action. The production of high levels of 2-hydroxyglutarate results in the inhibition of DNA repair pathways in cancer cells, and therefore the accumulation of damaged DNA. 2-Hydroxyglutarate is also known for its role as a marker of renal cell carcinomas and in tissues under oxygen limitation or hypoxia conditions such as hepatocellular carcinomas or colon carcinomas; it thus has a role in kidney and colon cancers.
- Inhibition of DNA repair by 2-hydroxyglutarate has been reported in other types of cancer: blood, skin, liver, lymph, prostate, thyroid, stomach, breast, pancreas, pituitary (Ye, D., Guan, K.-L. & Xiong, Y. Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates. Trends in cancer 4, 151-165 (2018)). 2-Hydroxyglutaric aciduria is a group of neurometabolic diseases with a broad clinical spectrum ranging from severe neonatal manifestations to progressive forms, and asymptomatic cases, characterized biochemically by elevated levels of 2-hydroxyglutaric acid in plasma, cerebrospinal fluid and urine.
- L-2-hydroxyglutaric aciduria is characterized by psychomotor retardation, cerebellar ataxia and epilepsy, and D-2-hydroxyglutaric aciduria (see this term) by variable metabolic, neurological and dysmorphic manifestations.
- Mutations in the L2HGDH (14q22.1) gene have been associated with L-2-hydroxyglutaric aciduria, and mutations in the D2HGDH (2q37.3) and IDH2 (15q26.1) genes have been associated with D-2-hydroxyglutaric aciduria.
- There is no cure for diseases that have a degenerative effect on cells such as neurons and motor nerve cells, only interventions to improve the management of patients with diseases that have a degenerative effect on neurons and muscle nerve cells: early diagnosis, physical health optimization, cognitive and well-being activities, screening and treatment of physical and psychological comorbidities.
- In addition, the main cancer treatments are chemotherapy and radiotherapy, which have limited effectiveness allowing a low survival rate and very heavy side effects such as hair loss, nausea and vomiting, diarrhea, decrease in white blood cells, red blood cells and platelets, lesions in the mouth, numbness or tingling sensations in the hands or feet, skin disorders and hand-foot syndrome, changes in the color and weakening of the nails, muscle and joint pain, menstrual cycle disorders, fatigue disorders, allergic reactions, damage to healthy cells by irradiation of healthy tissue next to the tumor, sexual disorders, fertility problems, inflammatory reaction, effects on blood cells. There is also no treatment for L- or D-2-hydroxyglutaric aciduria. In the case of D-2-hydroxyglutaric aciduria, epilepsy control is present; the prognosis depends entirely on the severity of the clinical picture and the progression of the disease, which cannot be predicted. In addition, the prognosis for L-2-hydroxyglutaric aciduria is poor for these patients, although most reach adulthood.
- Thus, there is a great need for an effective treatment of both neurodegenerative diseases and cancers, in particular brain, kidney, colon and intestinal tumors, capable of acting on the synthesis of 2-hydroxyglutarate, that is easy to administer and that has no side effects.
- To meet this need, the invention targets the use of specific bacteria of the human intestinal microbiota, in particular bacteria of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus.
- Bacteria of the family Christensenellaceae, including the genus Christensenella, have already been studied and described. This is the case in particular for Christensenella minuta, Christensenella massiliensis and Christensenella timonensis. Christensenella minuta in particular was described for the first time in 2012. In 2014, a study showed that it was the most heritable taxon in a cohort of British twins and that its presence is associated with a low body mass index. This correlation between Christensenella minuta and low body mass index was then observed in a dozen studies published since 2014 in geographically diverse populations. Finally, patent application US 2018/255819 describes the use of bacteria from the Christensenellaceae family in the treatment of obesity.
- Bacteria of the Parasutterella genus have already been studied and described. This is particularly the case for Parasutterella excrementihominis and Parasutterella secunda, which have been observed in several studies, without causal explanation. Parasutterella excrementihominis was first described in 2009 and Parasutterella secunda was first described in 2011. Other species have also been studied. This is the case for Parasutterella mc1, which has been associated with the abundance of certain metabolites in healthy mice.
- Bacteria of the Negativibacillus genus have been described. This is the case for Negativibacillus massiliensis, which was described in 2016. Bacteria of the Negativibacillus genus were characterized according to the description presented in “Negativibacillus massiliensis” gen. Nov., sp. Nov., isolated from human left colon, D. Ricaboni, M. Mailhe, V. Vitton, C. Andrieu, P.-E. Fournier, D. Raoult, New Microbe and New Infect 2017; 17: 36-38. No therapeutic use of bacteria of the Negativibacillus genus has ever been described or envisaged.
- Bacteria of the Massiliomicrobiota genus have been studied little. Massiliomicrobiota timonensis and Massiliomicrobiota escudieri are known in particular.
- Massiliomicrobiota timonensis was described for the first time in 2016. Massiliomicrobiota escudieri was described for the first time in 2018. Bacteria of the Massiliomicrobiota genus have been characterized according to the description presented in “Massiliomicrobiota timonensis,” a new bacterial species isolated from the human gut, S. Ndongo, S. Khelaifia, P.-E. Fournier, D. Raoult, New Microbe and New Infect 2016; 13: 25-26 and in “Massiliomicrobiota escudieri sp. nov. isolated as part of a culturomics exploration of the gut microbiota of renal cancer patients,” unpublished, Tidjani Alou, M., Derosa, L. and Zitvogel, L., submitted (11 Jun. 2018) U1015, Institut Gustave Roussy, 114 rue Edouard Vaillant, Villejuif 94800, France, Metropolitan. No therapeutic use of bacteria of the Massiliomicrobiota genus has ever been described or envisaged.
- Surprisingly, and according to the invention:
-
- bacteria of the Christensenellaceae family, in particular of the Christensenella genus, and in particular Christensenella minuta, Christensenella massiliensis and Christensenella timonensis,
- bacteria of the Parasutterella genus, in particular Parasutterella excrementihominis and Parasutterella secunda,
- bacteria of the Negativibacillus genus, in particular Negativibacillus massiliensis,
- bacteria of the Massiliomicrobiota genus, in particular Massiliomicrobiota timonensis and Massiliomicrobiota escudieri, and
- mixtures of at least two of these bacteria,
when administered to humans or animals, are capable of acting on 2-hydroxyglutarate, the cause of neurodegenerative diseases and cancers.
- This is why the subject of the invention is a bacterium of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one disease characterized by excess 2-hydroxyglutarate in humans or animals, in particular neurodegenerative diseases and cancers.
- Advantageously, such bacteria, when they are administered to a human or an animal exhibiting a neurodegenerative disease or cancer, are capable of acting on the excess 2-hydroxyglutarate produced in these diseases.
- For its use in the prevention or treatment of diseases characterized by excess 2-hydroxyglutarate in humans or animals, in particular in the prevention or treatment of neurodegenerative diseases and/or cancers, the bacteria of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus are preferably used in compositions. The invention therefore also relates to compositions comprising at least one bacterium of the Christensenellaceae family, preferably of the Christensenella genus, and/or a bacterium of the Parasutterella genus and/or a bacterium of the Negativibacillus genus and/or a bacterium of the Massiliomicrobiota genus, for its use in the prevention or treatment of diseases characterized by excess 2-hydroxyglutarate in humans or animals, in particular in the prevention or treatment of neurodegenerative diseases and/or cancers.
- Other features and advantages will become apparent from the detailed description of the invention that follows.
-
FIG. 1 demonstrates the antiproliferative effect of the supernatants of bacteria according to the invention, in particular 3 strains of C. minuta on a human colon adenocarcinoma cell line, the HTC-116 line, after 24 and 48 hours of treatment. -
FIG. 2 demonstrates the antiproliferative effect of the supernatants of bacteria according to the invention, in particular 3 strains of C. minuta on a human hepatocarcinoma cell line, the HepG2 line, after 24 and 48 hours of treatment. - Within the meaning of the invention, “excess” or “hyperproduction” of 2-hydroxyglutarate means an excessive production of 2-hydroxyglutarate relative to the production in a healthy person or animal without pathology.
- Within the meaning of the invention, “disease characterized by excess 2-hydroxyglutarate” or “disease characterized by hyperproduction of 2-hydroxyglutarate” means a disease whereof at least one cause is the excess or hyperproduction of 2-hydroxyglutarate in the body of the sick person or animal. This may in particular include a neurodegenerative disease or cancer.
- Within the meaning of the invention, “marker” of a disease means a molecule or a substance whose assay makes it possible to follow the evolution of said disease.
- Bacteria According to the Invention
- The invention therefore relates to a bacterium of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one disease characterized by excess 2-hydroxyglutarate in humans or animals.
- Bacteria of the Negativibacillus genus have been characterized according to the description presented in “Negativibacillus massiliensis” gen. Nov., sp. Nov., isolated from human left colon, D. Ricaboni, M. Mailhe, V. Vitton, C. Andrieu, P.-E. Fournier, D. Raoult, New Microbe and New Infect 2017; 17: 36-38 and in “Massiliomicrobiota escudieri sp. nov. isolated as part of a culturomics exploration of the gut microbiota of renal cancer patients,” unpublished, Tidjani Alou, M., Derosa, L. and Zitvogel, L., submitted (11 Jun. 2018) U1015, Institut Gustave Roussy, 114 rue Edouard Vaillant, Villejuif 94800, France, Metropolitan.
- Bacteria of the Massiliomicrobiota genus have been characterized according to the description presented in “Massiliomicrobiota timonensis,” a new bacterial species isolated from the human gut, S. Ndongo, S. Khelaifia, P.-E. Fournier, D. Raoult, New Microbe and New Infect 2016; 13: 25-26.
- In particular, the invention relates to a bacterium of the Christensenellaceae family, in particular of the Christensenella genus, and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one neurodegenerative disease and/or of at least one cancer in humans or animals.
- According to a variant, the invention relates to a bacterium of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one neurodegenerative disease chosen from Alzheimer's disease, dementia, Parkinson's disease and associated disorders, prion diseases, neuromuscular diseases, Huntington's disease, spinocerebellar ataxia, progressive spinal muscular atrophy and amyotrophic lateral sclerosis.
- According to another variant, the invention relates to a bacterium of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one brain and/or kidney and/or liver and/or colon cancer, in humans or animals.
- Preferably, the invention relates to a bacterium of the Christensenellaceae family and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or the treatment of at least one brain and/or kidney and/or liver and/or colon cancer, in humans or animals.
- According to another variant, the invention relates to a bacterium of the Parasutterella genus, for its use in the prevention and/or treatment of at least one neurodegenerative disease, preferably chosen from Alzheimer's disease, dementia, Parkinson's disease and related disorders, prion diseases, neuromuscular diseases, Huntington's disease, spinocerebellar ataxia, progressive spinal muscular atrophy and amyotrophic lateral sclerosis.
- According to the invention, the bacteria of the Christensenellaceae family and/or the bacteria of the Parasutterella genus and/or the bacteria of the Negativibacillus genus and/or the bacteria of the Massiliomicrobiota genus, when they are administered to a human or an animal presenting a neurodegenerative disease, are capable of acting on the excess molecules produced in a neurodegenerative disease or cancer, in particular on 2-hydroxyglutarate.
- In diseases with a degenerative effect on neurons, the decrease in the amount of 2-hydroxyglutarate is a sign of the reduction in these diseases with a degenerative effect on neurons, that is to say, the bacteria at the origin of this production are less stimulated. From then on, the excessive production responsible for the disease having a degenerative effect is slowed down and the system gradually returns to normal. In particular, a substrate of 2-hydroxyglutarate, glutarate, decreases when 2-hydroxyglutarate increases. Thus, a return to normal through a decrease in 2-hydroxyglutarate is accompanied by an increase in glutarate.
- In cancers, the decrease in the synthesis of 2-hydroxyglutarate is the sign of reduced inhibition of the DNA repair pathways, that is to say, the bacteria at the origin of this production are less stimulated. From then on, the excessive production responsible for DNA repair inhibition is slowed down and the system gradually returns to normal. In particular, a substrate of 2-hydroxyglutarate, glutarate, decreases when 2-hydroxyglutarate increases. Thus, a return to normal through a decrease in 2-hydroxyglutarate is accompanied by an increase in glutarate.
- In 2-hydroxyglutaric aciduria, the reduction in 2-hydroxyglutarate synthesis is the sign of the reduction in the clinical symptoms associated with this disease. In particular, a substrate of 2-hydroxyglutarate, glutarate, decreases when 2-hydroxyglutarate increases. Thus, a decrease in 2-hydroxyglutarate is accompanied by an increase in glutarate.
- Where the useful bacteria according to the invention are administered to humans or animals in an effective quantity for an action on 2-hydroxyglutarate, that is to say, to reduce its production in the body. According to a suitable embodiment, the bacterium or bacteria can be administered at a dose of 109 to 1012 colony-forming units (CFU) per day, regardless of the weight of the person or animal. It is preferably a single dose, i.e., administered once daily, or a dose before each meal (three times a day).
- The useful bacterium or bacteria according to the invention are:
-
- bacteria of the Christensenellaceae family, preferably of the genus Christensenella. It may be, in particular, Christensenella massiliensis, Christensenella timonensis and/or Christensenella minuta. According to a particularly suitable variant, it is Christensenella minuta. These bacteria can be isolated from human stools for example according to the protocols published by Morotomi et al., 2012 (Morotomi, M., Nagai, F. & Watanabe, Y. Description of Christensenella minuta gen. nov., sp. nov., isolated from human faeces, which forms a distinct branch in the order Clostridiales, and proposal of Christensenellaceae fam nov. INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY 62, 144-149 (2012)) and NDongo et al., 2016 (Ndongo, S., Dubourg, G., Khelaifia, S., Fournier, P. E. & Raoult, D. Christensenella timonensis, a new bacterial species isolated from the human gut. New Microbes and New Infections 13, 32-33 (2016)). These documents also describe the culture methods of the useful bacteria according to the invention.
- bacteria of the Parasutterella genus. It may in particular be Parasutterella excrementihominis and Parasutterella secunda. These bacteria can be isolated from human stool for example according to the protocols published by Nagai et al. 2009 (Parasutterella excrementihominis gen. nov., sp. nov., a member of the family Alcaligenaceae isolated from human faeces Nagai F Morotomi M Sakon H Tanaka R, International Journal of Systematic and Evolutionary Microbiology, 2009) and Morotomi et al. 2011 (Parasutterella secunda sp. nov., isolated from human faeces and proposal of Sutterellaceae fam. nov. in the order Burkholderiales, Morotomi M Nagai F Watanabe Y, International Journal of Systematic and Evolutionary Microbiology, 2011). These documents also describe the culture methods of the useful bacteria according to the invention.
- bacteria of the Negativibacillus genus, preferably Negativibacillus massiliensis. These bacteria can be isolated from human stool for example according to the protocols published by Fournier et al. 2016 (“Negativibacillus massiliensis” gen. nov., sp. nov., isolated from human left colon, Fournier P Ricaboni D Vitton V Raoult D Andrieu C Mailhe M, New Microbes and New Infections, 2016). This document also describes the culture methods of the useful bacteria according to the invention.
- bacteria of the genus Massiliomicrobiota. It may in particular be Massiliomicrobiota timonensis and Massiliomicrobiota escudieri. According to a particularly suitable variant, it is Massiliomicrobiota timonensis. These bacteria can be isolated from human stool for example according to the protocol published by Ndongo et al. 2016 (“Massiliomicrobiota timonensis,” a new bacterial species isolated from the human gut. Ndongo S Khelaifia S Fournier P Raoult D. New microbes and new infections, 2016 vol: 13 pp: 25-6). New Microbes and New Infections 13, 32-33 (2016)). This document also describes the culture methods of the useful bacteria according to the invention.
- and mixtures of at least two of these bacteria.
- The useful bacterium or bacteria according to the invention, for their previously described use, are preferably administered in a composition.
- Composition Comprising Bacteria According to the Invention
- The invention therefore also relates to a composition comprising at least one bacterium of the Christensenellaceae family and/or a bacterium of the Parasutterella genus and/or a bacterium of the Negativibacillus genus and/or a bacterium of the Massiliomicrobiota genus, in the prevention and/or treatment of diseases characterized by excess 2-hydroxyglutarate, in particular neurodegenerative diseases and/or cancers, in humans or animals. The bacterium or bacteria are present in an effective amount in the composition, allowing an effect on the 2-hydroxyglutarate and on the disease(s) to be treated, in particular the neurogenerative diseases and/or cancers, of the treated persons or animals.
- Preferably, the useful composition according to the invention comprises 106 to 1012 colony-forming units (CFU) of bacteria of the Christensenellaceae family and/or of bacteria of the Parasutterella genus and/or of bacteria of the Negativibacillus genus and/or of bacteria of the Massiliomicrobiota genus per daily dose of composition to be administered. Preferably, this corresponds to a daily dose of bacteria to be administered, regardless of the weight of the person or the animal. Preferably, this dose is administered once per day.
- The useful composition according to the invention may be in liquid form. It may in particular comprise bacteria of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus and a culture medium for said bacteria that makes it possible to preserve them. This medium may be, for example, Columbia agar medium for bacteria of the Christensenellaceae family, bacteria of the Negativibacillus genus, bacteria of the Massiliomicrobiota genus, or BTU medium for bacteria of the Parasutterella genus, anaerobic enriched with sheep blood, or an equivalent medium containing no animal byproduct.
- According to one variant, the useful composition according to the invention may be in solid form. In this case, the bacteria may be present in freeze-dried form, and may also comprise excipients such as, for example, microcrystalline cellulose, lactose, sucrose, fructose, levulose, starches, stachyose, raffinose, amylum, calcium lactate, magnesium sulphate, sodium citrate, calcium stearate, polyvinylpyrrolidone, maltodextrin, galactooligosaccharides, fructooligosaccharides, pectins, beta-glucans, lactoglobulins, isomaltooligosaccharides, polydextroses, sorbitol and/or glycerol.
- The useful compositions according to the invention may in particular be in the form of powder, microencapsulated powder, gelcap, capsule, tablet, lozenge, granules, emulsion, suspension or suppository. According to a particularly suitable embodiment, they may be in a gastro-resistant form, such as a coated tablet containing microencapsulated bacteria.
- When the compositions are in solid form, they are preferably packaged in capsules or in a coating hermetically sealed against light and oxygen, maintained at an ambient temperature of between 15° C. and 40° C. and a humidity level between 3% and 70%.
- The bacteria can be used alive, or inactivated, for example by heat, exposure to an appropriate pH, gamma radiation or high pressure.
- They can all be alive or all inactivated.
- Preferably, at least part of the bacteria is made up of live bacteria, in particular at least 50% (by number), even more preferably at least 90% (by number).
- Thus, according to a suitable embodiment, the bacteria present in the useful composition according to the invention are at least 50% living bacteria (by number), preferably at least 90% living bacteria (by number), and even more preferentially all living.
- The useful bacteria according to the invention, and in particular the compositions that include them, can be administered orally, topically, through the lungs (inhalation) or rectally.
- The useful compositions according to the invention, in addition to the useful bacteria according to the invention, can comprise other compounds, such as:
-
- at least one probiotic, and/or
- at least one bacterium making it possible to create an anaerobic environment favorable to the bacteria present in the composition, such as at least one bacterium chosen from bacteria of the genus Lactobacillus spp., Bifidobacterium spp., Streptococcus spp. and/or at least one other organism promoting the anaerobic conditions necessary for the survival of Christensenellaceae, such as at least one yeast chosen from Saccharomyces spp. or microorganisms of the Methanobacteriaceae family, and/or
- at least one bacterium associated with the ecosystem of the bacteria present in the composition, since they facilitate their survival in the intestine, such as at least one bacterium chosen from bacteria of the phylum Firmicutes, Bacteroidetes, Actinobacteria, Tenericutes, betaproteobacteria and Verrucomicrobia, and/or
- at least one bacterium chosen from bacteria of the order Burkholderiales, Clostridales, Verrucomicrobiales, Aeromonadales, Alteromonadales, ML615J-28, RF32, YS2, of the family Clostridiaceae, Lachnospiraceae, Erysipelotrichaceae, Ruminococcaceae, Bacteroidaceae, Enterococcaceae, Rikenellaceae, Dehalobacteriaceae, Veillonellaceae, Lactobacillaceae and/or
- at least one bacterium chosen from bacteria of the genus Faecalibacterium, Akkermansia, Eubacterium, Sutterella, Burkholderia, Derxia, Brackiella, Oligella, Pelistega, Taylorella, Tetrathiobacter, Advenella, Alcicaligenes, Pigmentiphaga, Kerstersia, Achromobacter, Bordetella, Castellaniella, Pusillimonas, Turicibacter and Oscillospira such as, for example, Faecalibacterium prausnitzii, Akkermansia muciniphila, Eubacterium halii, Oscillospira guilliermondii, Turicibacter sanguinis, Suterella parvirubra, Derxia gummosa, Brackiella oedipodis, Oligella urethralis, Pelistega europea, Taylorella equigenitalis, Tetrathiobacter kashmirensis, Advenella incenata, Alcaligenes faecalis, Pigmentiphaga kullae, Kerstersia gyiorum, Achromobacter xylosoxidans, Bordetella pertussis, Castellaniella defragrans, Pusillimonas noertemannii and/or
- at least one prebiotic such as for example at least one prebiotic chosen from galactooligosaccharides, fructooligosaccharides, inulins, arabinoxylans, beta-glucans, lactoglobulins and/or beta-caseins, and/or
- at least one polyphenol such as for example at least one polyphenol chosen from quercetin, kaempferol, resveratrol, flavones (such as luteolin), flavan-3-ols (such as catechins), flavanones (such as naringenin), isoflavones, anthocyanidins, proanthocyanidins, and/or
- at least one mineral and/or at least one vitamin and/or at least one nutritional agent, and/or
- at least one active pharmaceutical ingredient, preferably at least one active pharmaceutical ingredient having a therapeutic effect on the pathology or pathologies (diseases having a degenerative effect on neurons or muscle nerve cells and/or cancer(s) in particular) for which the bacteria present in the composition are used, such as for example:
- Drugs against the degenerative effect of neurons and muscle nerve cells Donepezil, Rivastigmine, Galantamine, Memantine, Riluzole, Nusinersen, psychotropics, thinners, neuroleptics
- Chemotherapy drugs including targeted therapies or biotherapies, hormone therapy or immunotherapy
- The invention is now illustrated by examples of useful bacteria according to the invention, methods for culturing these bacteria, examples of compositions containing them and test results demonstrating the effectiveness of bacteria of the Christensenellaceae family and/or bacteria of the Parasutterella genus and/or bacteria of the Negativibacillus genus and/or bacteria of the Massiliomicrobiota genus on 2-hydroxyglucarate and consequently on the diseases induced by an excess of this molecule.
- The Christensenella minuta bacteria can be cultured according to the operating protocol described below.
-
- 1/ Dissolve a dehydrated RCM (“Reinforced Clostridial Medium”) medium in distilled water
- 2/ Add 0.5 mL/L of resazurin-Na solution (0.1% w/v)
- 3/ Bring to a boil and cool to room temperature while injecting a gaseous mixture of 80% N2 and 20% CO2
- 4/ Spread the medium under the same gaseous atmosphere in anoxic Hungate-type tubes or in serum vials, then autoclave
- 5/ Before use, add 1.0 g of sodium carbonate per liter from a sterile anoxic stock solution prepared with a gaseous mixture of 80% N2 and 20% CO2
- 6/ Check the pH of the medium after autoclaving and adjust the pH between 7.3 and 7.5, using a sterile anoxic stock solution of sodium bicarbonate (5% w/v) prepared in a gaseous atmosphere at 80% N2 and at 20% CO2.
- The Christensenella massiliensis bacteria can be cultured according to the operating protocol described below.
-
- 1/ Prepare a carboxymethylcellulose (N2/CO2) medium by following the instructions below provided by DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen), presented in Table 1.
-
TABLE 1 Casitone 30.0 g Yeast extract 5.0 g K2HPO4 5.0 g Na-resazurin solution (0.1% w/v) 0.5 mL L-Cysteine-HCl × H2O 0.5 g D-Glucose 4.0 g Cellobiose 1.0 g Maltose 1.0 g Na2CO3 1.0 g Meat filtrate (see Table 2) 1000 mL -
- 2/ Dissolve the different constituents listed in the table above, except cysteine, carbohydrates and carbonate.
- 3/ Boil the medium for 1 min, then let it cool to room temperature under a gaseous atmosphere containing 80% N2 and 20% CO2.
- 4/ Add 0.5 g/L of L-cysteine-HCl x H2O and pour it under the same gaseous atmosphere into Hungate-type tubes (for strains requiring meat particles, introduce these first into the tube; use 1 part meat particles to 4 or 5 parts liquid).
- 5/ Autoclave at 121° C. for 20 min.
- 6/ After autoclaving, add glucose, cellobiose, maltose and starch from sterile anoxic stock solutions prepared with 100% N2 gas and carbonate from a sterile anoxic stock solution prepared under gaseous mixtures at 80% N2 and 20% CO2.
- 7/ Adjust the pH of the medium to 7, if necessary.
- The composition of the meat filtrate is shown in Table 2.
-
TABLE 2 Ground meat (no fat) 500.0 g 1N NaOH 25.0 mL Distilled water 1000 mL - The meat filtrate is prepared as follows.
-
- a/ Use lean beef or horse meat.
- b/ Remove fat and connective tissue before chopping.
- c/ Mix the meat, water and NaOH, then boil for 15 minutes with stirring.
- d/ Allow to cool to room temperature, remove fat from the surface and filter, retaining meat particles and filtrate.
- e/ Add water to the filtrate to a final volume of 1000.0 mL.
- The bacteria must be grown under anaerobic conditions at 37° C.
- The Christensenella timonensis bacteria can be cultivated according to the same procedure as that described in Example 2 for Christensenella massiliensis.
- The Parasutterella excrementihominis bacteria can be cultured according to the operating protocol described below.
-
BTU=(ground meat medium+Formate/fumarate)+5% bovine serum -
- Ground meat medium
- Ground beef (fat free) (500.0 g)+distilled water (1000.0 mL)+1 N NaOH (25.0 mL).
- Use lean beef or horse meat. Remove fat and connective tissue before chopping. Mix the meat, the water and the NaOH, then boil for 15 minutes with stirring. Cool to room temperature, remove fat from the surface and filter while keeping both: meat particles and filtrate. Add water to the filtrate for a final volume of 1000.0 mL, and then add: casitone (30.0 g), yeast extract (5.0 g), K2HPO4 (5.0 g), resazurin (1.0 mg)
- Boil under a Nitrogen atmosphere, add 0.5 g/l of cystine and adjust the pH to 7.0. Distribute 7 mL of medium under anaerobic conditions in Hungate tubes containing the meat particles (use one part meat particles for 4 to 5 parts liquid). Autoclave at 121° C. for 30 min.
- To prepare the agar: use test tubes and put 15 g of agar therein for 1000.0 L of medium.
- In some cases, it is possible to add Haemin, Vitamin K1 or Vitamin K3 if needed.
- Add 1000.0 mL of medium after autoclaving: Haemin solution (10.0 mL)+Vitaline K1 or K3 solution (0.2 mL).
- Haemin solution: dissolve 50 mg of Haemin in 1 mL of 1 N NaOH, add 100 mL of distilled water and sterilize by filtration, store refrigerated.
- Vitamin K1 solution: dissolve 0.1 mL of vitamin K1 in 20 mL of 95% ethanol and sterilize by filtration. Store refrigerated in an amber bottle.
- Vitamin K3 solution:
- Dissolve 5 mg/mL of vitamin K3 in 10 mL of 95% ethanol and sterilize by filtration.
- Store refrigerated in an amber bottle.
- Formate/fumarate solution
- Mix Na-formate (6.0 g)+Na-fumarate (6.0 g)+distilled water (100.0 mL). Sterilize by filtration. Add 30 microliter per mL of medium 78 before inoculation.
- The Parasutterella secunda bacteria can be cultured according to the operating protocol described below.
- EG Medium:
-
- Add 0.2 g of L-cystine to 50 mL of 1 N HCl and mix vigorously. Then add: 2.4 g of Lab-Lemco powder, 10.0 g of peptone proteose No3, 5.0 g of yeast extract, 4.0 g of Na2HPO4, 1.5 g of glucose, 0.5 g of soluble starch, 15.0 g of agar, 0.5 g of L-cysteine HCl H2O, then distilled water to reach a volume of 950.0 mL.
- Adjust the pH to 7.6-7.8.
- Autoclave and cool to 50° C., then add 50.0 mL of horse blood aseptically.
- Mix vigorously and distribute in appropriate sterile containers (Petri dishes or sterile tubes).
- Or Columbia blood agar medium with 5% horse blood:
-
- Prepare the Columbia blood agar base (Oxoid CM331) according to the instructions, sterilize and cool to 45° C.
- add 50.0 mL of aseptically defibrinated horse blood.
- mix and disperse quickly in appropriate sterile containers (Petri dishes or sterile tubes).
- The Negativibacillus massiliensis bacteria can be cultured according to the operating protocol described below.
- Species obtained by growth on Columbia agar medium (bioMérieux, Marcy I'Etoile, France) with 5% sheep blood under anaerobic atmosphere (anaeroGEN, Oxoid, Dardilly, France) after 14 days of enrichment of a fresh colon sample left placed in a bottle cultured in blood (Becton Dickinson, Pont de Claix, France) with 5 mL of sheep blood (bioMérieux) and 5 mL of 0.2 μm filtered rumen (Thermo Fisher Scientific, Villebon-sur-Yvette, France) at 37° C. Then 5 days of anaerobic incubation on Columbia agar medium enriched with 5% sheep blood
- Massiliomicrobiota timonensis can be cultivated according to the operating protocol described as follows:
-
- Columbia bioMérieux agar medium, Marcy I'Etoile, France) enriched with 5% Columbia agar sheep blood
- at 37° C.
- anaerobic atmosphere generated by AnaeroGen (bioMérieux).
- 72 hours of incubation
- The Massiliomicrobiota escudieri bacteria can be cultivated according to the same procedure as that described in Example 7 for Massiliomicrobiota timonensis.
- An example of a useful composition according to the invention in liquid form is a composition comprising Christensenella minuta 109 CFU/mL in the RCM anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- The composition of Example 9 was obtained from an RCB (“research cell bank”) prepared with Christensenella minuta 1010 CFU/mL and stored frozen at −20° C. in a bag hermetically sealed to oxygen.
- The frozen composition must be warmed to room temperature until a liquid form is found before use.
- An example of a useful composition according to the invention in liquid form is a composition comprising Christensenella massiliensis 109 CFU/mL in the carboxymethylcellulose anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- The composition of Example 10 was obtained from an RCB (“research cell bank”) prepared with Christensenella massiliensis 1010 CFU/mL and stored frozen at −20° C. in a bag hermetically sealed to oxygen.
- The frozen composition must be warmed to room temperature until a liquid form is found before use.
- An example of a useful composition according to the invention in liquid form is a composition comprising Christensenella timonensis 109 CFU/mL in the carboxymethylcellulose anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- The composition of Example 11 was obtained from an RCB (“research cell bank”) prepared with Christensenella timonensis 1010 CFU/mL and stored frozen at −20° C. in a bag hermetically sealed to oxygen.
- The frozen composition must be warmed to room temperature until a liquid form is found before use.
- An example of a useful composition according to the invention in liquid form is a composition comprising Parasutterella excrementihominis 109 CFU/mL in the BTU anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- The composition of Example 12 was obtained from an RCB (“research cell bank”) prepared with Parasutterella excrementihominis 1010 CFU/mL and stored frozen at −20° C. in a bag hermetically sealed to oxygen.
- The frozen composition must be warmed to room temperature until a liquid form is found before use.
- An example of a useful composition according to the invention in liquid form is a composition comprising Parasutterella secunda 109 CFU/mL in the EG culture medium or the Columbia anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- The composition of Example 13 was obtained from an RCB (“research cell bank”) prepared with Parasutterella secunda 1010 CFU/mL and stored frozen at −20° C. in a bag hermetically sealed to oxygen.
- The frozen composition must be warmed to room temperature until a liquid form is found before use.
- An example of a useful composition according to the invention in liquid form is a composition comprising Negativibacillus massiliensis 109 CFU/mL in the EG culture medium or the Columbia anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- The composition of Example 14 was obtained from an RCB (“research cell bank”) prepared with Negativibacillus massiliensis 1010 CFU/mL and stored frozen at −20° C. in a bag hermetically sealed to oxygen.
- The frozen composition must be warmed to room temperature until a liquid form is found before use.
- An example of a useful composition according to the invention in liquid form is a composition comprising Massiliomicrobiota timonensis 109 CFU/mL in the EG culture medium or the Columbia anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- The composition of Example 15 was obtained from an RCB (“research cell bank”) prepared with Massiliomicrobiota timonensis 1010 CFU/mL and stored frozen at −20° C. in a bag hermetically sealed to oxygen.
- The frozen composition must be warmed to room temperature until a liquid form is found before use.
- An example of a useful composition according to the invention in liquid form is a composition comprising Massiliomicrobiota escudieri 109 CFU/mL in the EG culture medium or the Columbia anaerobic culture medium described above, modified to contain no product of animal origin and enriched with 5% glycerol.
- The composition of Example 16 was obtained from an RCB (“research cell bank”) prepared with Massiliomicrobiota escudieri 1010 CFU/mL and stored frozen at −20° C. in a bag hermetically sealed to oxygen.
- The frozen composition must be warmed to room temperature until a liquid form is found before use.
- An example of a useful composition according to the invention in liquid form can be obtained by mixing at least one composition of Examples 9 to 16 with at least one distinct composition from Examples 9 to 16.
- An example of a useful composition according to the invention in freeze-dried form can be obtained by freeze-drying one of the compositions of Examples 9 to 17 in the frozen state.
- In Vitro Demonstration of the Treatment Effect on Diseases Characterized by Excess 2-Hydroxyglucarate, in Particular Neurodegenerative Diseases and Cancers
- The objective of this study is to demonstrate in vitro the treatment effect of bacteria according to the invention on neurodegenerative diseases and cancers. The demonstration was carried out on 2-hydroxyglutarate and its precursor, glutarate.
- The procedure of the study is described below.
-
- 1/ Fermentation protocol using feces of human origin containing Christensenella spp., Parasutterella spp., Negativibacillus spp., Massiliomicrobiota spp.:
- The donors must not have taken antibiotics during the six months preceding the experiment and have no history of gastrointestinal disorders. The donors were between 18 and 60 years old.
- The collection of fresh samples of their feces is obtained in sterile plastic containers, stored in anaerobic bottles containing a 2.5 L sachet of AnaeroGen™ from Oxoid™ O2<0.1%; CO2: 7-15%). These samples were brought to the laboratory within two hours of their production.
- Feces samples were diluted 1/5 (weight/volume) in phosphate buffered saline (1 M) (PBS), pH 7.4. The suspension was homogenized in a stomacher for 120 seconds.
- Basic nutrient medium: the basic nutrient medium was prepared from 2 g/L tryptone soy broth, 2 g/L yeast extract, 0.1 g/L NaCl, 0.04 g/L K2HPO4, 0.01 g/L MgSO3·7H2O, 0.01 g/L CaCl2·6H2O, 2 g/L NaHCO3, 0.5 g/L L-cystine HCl, 2 mL/L tween 80, 10 μL/L vitamin K1, 0.05 g/L heme, 0.05 g/L bile salts, 4 ml/L resazarin (pH 7)
- Fermentation in a biofermenter: The 20 mL capacity biofermenters contained 18 mL of autoclaved base nutrient medium (121° C. for 15 minutes) poured aseptically into the sterile biofermenters. This system was allowed to stand overnight with oxygen-free nitrogen bubbling through the medium at a rate of 2 mL/min. The pH was maintained between 6.7 and 6.9 using HCl or NaOH (0.5 M). The temperature of each biofermenter was controlled at 37° C. and the contents of the container were homogenized with a magnetic mixer
- a mixture of predigested proteins (0.35 g) was added to the containers before inoculation with 2 mL of fecal inocula at TO. The predigested proteins were obtained according to the gastrointestinal digestion protocol adapted from that of Versantvoort et al (2005).
- the samples were collected before fermentation (T0) and after 48 hours of fermentation (T48), and frozen at −80° C. until analysis.
- 2/ Quantification of 2-hydroxyglutarate and glutarate. 50 μL of samples collected and stored at −80° C. was mixed with 20 μL of Milli-Q water containing internal standards.
- The mixture was mixed and filtered through a 5-kDa threshold filter to remove macromolecules.
- The metabolites were detected by capillary electrophoresis-time-of-flight mass spectrometry (CE-TOFMS) analyses. The peak detection limit was determined based on the signal-to-noise ratio, S/N=3.
-
Relative peak area=(metabolite peak area)/(internal standard peak area×amount of sample). -
- 3/ Quantification of Christensenella spp., Parasutterella spp., Negativibacillus spp., Massiliomicrobiota spp.
- The DNA contained in the samples was extracted using the NucleoSpin®96 Soil kit from Macherey-Nagel according to the manufacturer's instructions.
- The total extracted DNA was then randomly fragmented into 350 bp fragments and then used to build a library using the NEBNext Ultra II kit by New England Biolabs according to the manufacturer's instructions.
- The library was then sequenced using 2×150 bp paired-end sequencing on an Illumina HiSeq platform.
- The abundance of bacteria was measured by creating a metagenomic species catalog (MGS) from a reference catalog containing 22 M genes. These MGSs were then associated with an appropriate taxonomic level. In the case of Christensenella, these were detected at the genus level and are therefore referred to in this experiment as Christensenella spp.
- The relative amount of 2-hydroxyglutarate and the relative abundance of Christensenella spp., Parasutterella spp., Negativibacillus spp., Massiliomicrobiota spp were analyzed and correlated, obtaining a linear regression of R=−0.42, R=−0.41, R=−0.31, R=−0.26 (n=18).
- The relative amount of glutarate and the relative abundance of Christensenella spp., Parasutterella spp., Negativibacillus spp., Massiliomicrobiota spp were analyzed and correlated, obtaining a linear regression of R=0.41, R=0.43, R=0.51, R=0.36 (n=18).
- The results are shown in Table 3.
-
TABLE 3 Relative Relative Relative Relative abundance of abundance of abundance of abundance of Relative Relative Christensenella Parasutterella Negativibacillus Massiliomicrobiota amount of amount of spp spp spp spp 2-hydroxyglutarate glutarate Samples (×10−3) (×10−3) (×10−2) (×10−3) (×10−5) (×10−5) V1 7.55 560.67 9.02 0 3.47 0 V2 3.18 258.72 2.48 4.14 3.01 0 V3 8.19 266.78 0 1.23 0 5.4332 V4 2.6 1362.44 1.90 0 3.24 0 V5 1.26 5.21 0 0 6.06 0 V6 2.87 1163.56 0 0 2.91 0 V7 7.20 7297.76 268.30 1.29 0 31.44 V8 2.91 2456.31 45.18 1.19 0 22.301 V9 6.32 7271.23 0 1.23 0 20.88 V10 1.21 196.88 2.91 0 0 13.56 V11 4.23 231.77 121.61 0 0 21.43 V12 1.49 6342.36 0 0 0 19.68 V13 9.83 4535.74 262.37 5.84 0 41.08 V14 4.12 2517.99 13.96 4.31 0 20.72 V15 6.45 4798.48 0 4.08 0 22.16 V16 2.02 544.48 8.85 0 3.31 22.54 V17 5.23 111.85 606.77 0 0 24.81 V18 7.57 17842.41 0 0 0 22.32 - A negative correlation is observed between the bacteria according to the invention and 2-hydroxyglutarate as well as a positive correlation between the bacteria according to the invention and glutarate, which demonstrates a protective effect of bacteria of the Massiliomicrobiota genus against neurodegenerative diseases and cancers.
- Thus, the bacteria according to the invention are able to act by decreasing the production of 2-hydroxyglutarate. They can therefore be used to prevent and/or treat neurodegenerative diseases and cancers.
- In Vitro Demonstration of the Antiproliferative Effect on Tumor Cells, in Particular HCT-116 Cells (Adenocarcinoma of the Colon).
- The objective of this study is to demonstrate in vitro the effect of bacteria according to the invention, in particular of C. minuta on the proliferation of tumor cells. The effect of the supernatants was evaluated after 24 h and 48 h of treatment of a human colon adenocarcinoma cell line, the HCT-116 line. The procedure is described below.
- Cell Culture
- The HCT-116 cell line was maintained in culture in McCoy's 5A medium supplemented with 10% fetal calf serum (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich) in a humid incubator at 37° C. and 5% CO2.
- Cell Treatment
- The HCT-116 cells were seeded at a density of 10,000 cells/well in a total volume of 100 μl in a 96-well plate. After 24 h of incubation, the culture medium was removed from the adherent cells and new medium supplemented with 10% stationary phase supernatant of C. minuta was added (DSMZ: DSM22607, C. minuta 1, C. minuta 2 or C. minuta 3 and in GAM control (bacterial culture medium)). Each condition was done in 4 replicates. The cells were incubated for an additional 24 or 48 hours.
- Proliferation Test
- Cell proliferation was determined using the CellTiter-Glo 2.0 assay kit (Promega). The measurements were carried out according to the manufacturer's instructions. Briefly, the plates were removed from the incubator and allowed to equilibrate at room temperature for 30 min, and an equal volume of CellTiter-Glo 2.0 reagent was added directly to the wells (100 μl). The plates were stirred at 300 rpm for 2 min using a rotary stirrer, then incubated at room temperature for 10 min. The reaction mixture was then transferred to a white-walled 96-well plate and the luminescent signal was measured using a microplate reader (FLUOstar Omega, BMG Labtech).
- Results
- The supernatants of the different bacterial strains of the species C. minuta DSMZ: DSM22607, C. minuta 1, C. minuta 2 and C. minuta 3 significantly reduce the proliferation of cells treated for 24 h and 48 h, compared to the “GAM” control, corresponding to the cells treated with the bacterial culture medium (GAM vs DSMZ: DSM22607, C. minuta 2, C. minuta 2 p<0.0001, GAM vs C. minuta 1 p=0.0002 at 24 h and GAM vs DSMZ: DSM22607 p=0.0002, GAM vs C. minuta 1 p=0.0016, GAM vs C. minuta 2 and C. minuta 3 p<0.0001 at 48 h, Dunnett's multiple comparisons test). Akt Inhibitor VIII is used as a positive control for blocking cell proliferation.
- Thus, the supernatants of the various tested bacteria according to the invention induce a reduction in the proliferation of tumor line HCT-116, making it possible to indicate a beneficial effect of the bacteria according to the invention in the inhibition of tumor development.
- In Vitro Demonstration of the Antiproliferative Effect on Tumor Cells, in Particular HepG2 Cells (Hepatocarcinoma).
- The objective of this study is to demonstrate in vitro the effect of bacteria according to the invention, in particular of C. minuta on the proliferation of tumor cells. The effect of the supernatants was evaluated after 24 h and 48 h of treatment of a human adenocarcinoma cell line, the HepG2 line. The procedure is described below.
- Cell Culture
- The HepG2 cell line was maintained in culture in DMEM medium supplemented with 10% fetal calf serum (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich) in a humid incubator at 37° C. and 5% CO2.
- The cell treatment and the proliferation test are identical to the test previously described on the HCT-116 line.
- The supernatants of the bacteria according to the invention significantly reduce the proliferation of the cells treated at 24 h and all the strains of C. minuta DSMZ: DSM22607, C. minuta 1, C. minuta 2 and C. minuta 3 at 48 h, compared to the “GAM” control, corresponding to the cells treated with the bacterial culture medium (GAM vs DSMZ: DSM22607 or C. minuta 3, p=0.0003 and GAM vs C. minuta 2 p=0.0008 at 24 h/GAM vs DSMZ: DSM22607, C. minuta 2, C. minuta 3 p<0.0001 and GAM vs C. minuta 1 p=0.0024 at 48 h, Dunnett's multiple comparisons test). Akt Inhibitor VIII is used as a control for blocking cell proliferation.
- Thus, the supernatants of the tested bacteria according to the invention induce a reduction in the proliferation of tumor line HepG2, making it possible to indicate a beneficial effect of the bacteria according to the invention in the inhibition of tumor development.
Claims (22)
1. A human intestinal microbiota bacterium selected from bacteria of the Christensenellaceae family, bacteria of the Negativibacillus genus and bacteria of the Massiliomicrobiota genus, for its use in the prevention and/or treatment of at least one disease characterized by excess 2-hydroxyglutarate in humans or animals.
2. The bacterium for its use according to claim 1 , in the prevention and/or the treatment of at least one neurodegenerative disease and/or of at least one cancer in humans or animals.
3. The bacterium for its use according to claim 1 , in the prevention and/or treatment of at least one neurodegenerative disease, chosen from Alzheimer's disease, dementia, Parkinson's disease and related disorders, prion diseases, neuromuscular diseases, Huntington's disease, spinocerebellar ataxia, progressive spinal muscular atrophy and amyotrophic lateral sclerosis.
4. Bacterium for its use according to claim 2 , in the prevention and/or the treatment of at least one brain and/or kidney and/or liver and/or colon cancer, in humans or animals.
5. Bacterium for its use according to claim 1 , characterized in that said bacterium is a bacterium of the Christensenella genus.
6. Bacterium for its use according to claim 1 , characterized in that said bacterium is selected from Christensenella massiliensis, Christensenella timonensis and Christensenella minuta, Negativibacillus massiliensis, and Massiliomicrobiota timonensis.
7. A composition comprising at least one human intestinal microbiota bacterium selected from bacteria of the Christensenellaceae family, bacteria of the Negativibacillus genus and bacteria of the Massiliomicrobiota genus for use in the prevention and/or treatment of diseases characterized by excess 2-hydroxyglutarate in humans or animals.
8. The composition for its use according to claim 7 , in the prevention and/or treatment of neurodegenerative diseases and/or of at least one cancer in humans or animals.
9. The composition for its use according to claim 8 , in the prevention and/or treatment of at least one neurodegenerative disease, chosen from Alzheimer's disease, dementia, Parkinson's disease and related disorders, prion diseases, neuromuscular diseases, Huntington's disease, spinocerebellar ataxia, progressive spinal muscular atrophy and amyotrophic lateral sclerosis.
10. The composition for its use according to claim 8 , in the prevention and/or the treatment of at least one brain and/or kidney and/or liver and/or colon cancer, in humans or animals.
11. The composition for its use according to claim 7 , characterized in that it also comprises at least one bacterium of the Christensenella genus.
12. The composition for its use according to claim 7 , characterized in that it comprises at least one bacterium chosen from Christensenella massiliensis, Christensenella timonensis and Christensenella minuta, Negativibacillus massiliensis and Massiliomicrobiota timonensis, or a mixture of at least two of these bacteria.
13. The composition for its use according to claim 7 , characterized in that it is in liquid form.
14. The composition for its use according to claim 7 , characterized in that it is in solid form.
15. The composition for its use according to claim 14 , characterized in that the bacteria are present in freeze-dried form.
16. The composition for its use according to claim 7 , characterized in that the bacteria present are at least 50% living bacteria (by number).
17. The composition for its use according to claim 7 , characterized in that the bacteria present are at least 90% living bacteria (by number).
18. The composition for its use according to claim 7 , orally, rectally, inhaled.
19. The composition for its use according to claim 7 , characterized in that it is in the form of powder, microencapsulated powder, gelcap, capsule, tablet, lozenge, granules, emulsion, suspension or suppository.
20. The composition for its use according to claim 7 , characterized in that it is in a gastro-resistant form.
21. The composition for its use according to claim 7 , characterized in that it comprises at least one probiotic and/or at least one prebiotic.
22. The composition for its use according to claim 7 , characterized in that it also comprises:
at least one polyphenol, and/or
at least one mineral and/or at least one vitamin and/or at least one nutritional agent, and/or
at least one active pharmaceutical ingredient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1906845A FR3097739B1 (en) | 2019-06-25 | 2019-06-25 | Bacteria of the intestinal microbiota and composition containing them for use in the prevention and/or treatment of diseases characterized by excess 2-hydroxyglutarate |
FRFR1906845 | 2019-06-25 | ||
PCT/EP2020/067637 WO2020260358A1 (en) | 2019-06-25 | 2020-06-24 | Intestinal microbiota bacteria and composition containing same for use in the prevention and/or treatment of diseases characterised by excess 2-hydroxyglutarate |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230330158A1 true US20230330158A1 (en) | 2023-10-19 |
Family
ID=68138455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/915,610 Pending US20230330158A1 (en) | 2019-06-25 | 2020-06-24 | Intestinal microbiota bacteria and composition containing same for use in the prevention and/or treatment of diseases characterised by excess 2-hydroxyglutarate |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230330158A1 (en) |
EP (1) | EP3989989A1 (en) |
FR (1) | FR3097739B1 (en) |
WO (1) | WO2020260358A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3541400A2 (en) * | 2016-11-18 | 2019-09-25 | Sanford Burnham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
FR3063646B1 (en) * | 2017-03-10 | 2021-07-30 | International Nutrition Res Company | BACTERIA SPECIFIC FOR THEIR USE AS A MEDICINAL PRODUCT, IN PARTICULAR FOR THE CONTROL OF OVERWEIGHT, OBESITY, CARDIOMETABOLIC DISEASES AND INFLAMMATORY DISEASES OF THE INTESTINE |
-
2019
- 2019-06-25 FR FR1906845A patent/FR3097739B1/en active Active
-
2020
- 2020-06-24 EP EP20739276.2A patent/EP3989989A1/en active Pending
- 2020-06-24 WO PCT/EP2020/067637 patent/WO2020260358A1/en unknown
- 2020-06-24 US US17/915,610 patent/US20230330158A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020260358A1 (en) | 2020-12-30 |
FR3097739A1 (en) | 2021-01-01 |
EP3989989A1 (en) | 2022-05-04 |
FR3097739B1 (en) | 2022-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Phloretin ameliorates dextran sulfate sodium-induced ulcerative colitis in mice by regulating the gut microbiota | |
Jiang et al. | Intestinal dysbacteriosis mediates the reference memory deficit induced by anaesthesia/surgery in aged mice | |
Ohishi et al. | Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele | |
ES2610829T3 (en) | Bifidobacterium strain | |
US20080003207A1 (en) | Treating inflammatory bowel disease with live bacteria | |
CN108367033A (en) | The method and composition of depressive symptom is treated or prevented using bifidobacterium longum | |
CN101646444B (en) | Prophylactic and/or therapeutic agent for functional dyspepsia | |
ES2760256T3 (en) | Composition | |
Knackstedt et al. | The role of thermal injury on intestinal bacterial translocation and the mitigating role of probiotics: A review of animal and human studies | |
BR112020019979A2 (en) | COMPOSITIONS AND METHODS FOR TREATING INTESTINAL INFLAMMATORY DISEASES | |
CN105012349A (en) | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation | |
RU2287335C1 (en) | Preparation "bacstitatin" for treating diseases of gastrointestinal tract | |
CN101849969A (en) | Application of butyric acid producing beneficial bacterium in preparing preparation for preventing and treating severe disease gut barrier injury and post-injury complication | |
US20230330158A1 (en) | Intestinal microbiota bacteria and composition containing same for use in the prevention and/or treatment of diseases characterised by excess 2-hydroxyglutarate | |
CN110087656A (en) | Application of the inosine in treatment T-reg lacks | |
RU2400235C1 (en) | Method of treating patients with intestinal dysbacteriosis | |
EP3856147A1 (en) | Methods and probiotic compositions for the treatment of bone disorders | |
US20230131906A1 (en) | Bacterium of the christensenellaceae family and composition containing same for the prevention and/or treatment of pathological muscle loss or of a disease characterised by pathological muscle loss | |
Bastani et al. | Health benefits of probiotic consumption | |
CN115838649A (en) | Microbial composition for intestinal flora blending and preparation method thereof | |
BR112013001369A2 (en) | use of a fermented soy extract, and pharmaceutical composition. | |
RU2310463C1 (en) | Hepatoprotective probiotic agent | |
KR102049522B1 (en) | Composition for Prohylaxis and Treatment of Infectious Disease by Salmonella Comprising GABA | |
RU2571495C1 (en) | Method of treating patients with intestinal disbacteriosis | |
RU2332993C2 (en) | Method for protecting human body from adverse influences of environment and composition to this effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOSCIENCES, YSOPIA, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAWADI, GEORGES;CLAUS, SANDRINE;RINALDI, LAURE;AND OTHERS;SIGNING DATES FROM 20221026 TO 20221027;REEL/FRAME:061828/0862 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: VERB BIOTICS, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YSOPIA BIOSCIENCES;REEL/FRAME:065580/0134 Effective date: 20231010 |